L’hypothèse d’une intervention dans le cadre de l’article

Buscando por novos alvos terapêuticos para o CaP, especialmente entre os genes envolvidos em vias de estresse oxidativo, encontramos a enzima SRXN1, cuja expressão mostrou-se aumentada nos estágios avançados do tumor prostático. Sua up regulação está associada ao pior prognóstico do CaP e a menor sobrevida dos pacientes. Essa enzima antioxidante tem papel importante na manutenção do equilíbrio redox intracelular, contribuindo com o processo de sobrevivência e progressão tumoral, uma vez que sua inibição reduziu a viabilidade de células cancerosas prostáticas. Assim, no contexto da medicina de precisão, nosso trabalho aponta a inibição da SRXN1 como uma potencial estratégia para o tratamento adjuvante do “CaP resistente à castração” em pacientes que tenham superexpressão dessa enzima. Nossos resultados também demonstraram que a expressão proteica e gênica da SRXN1 é diferentemente modulada por testosterona, flutamida, fibronectina e H2O2 em células prostáticas e que essa modulação depende dos

diferentes metabolismos celulares. Assim, considerando que o tumor prostático é altamente heterogêneo, ainda é necessário um melhor entendimento sobre como a expressão de SRXN1 é regulada nas diferentes fases de progressão do CaP para o desenvolvimento de novas estratégias de tratamento a partir do uso de inibidores específicos para SRXN1.

6. REFERÊNCIAS

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA. Cancer J. Clin. 68, 7–30 (2018).

2. Center, M. M. et al. International Variation in Prostate Cancer Incidence and Mortality Rates.

Eur. Urol. 61, 1079–1092 (2012).

3. Lilja, H., Ulmert, D. & Vickers, A. J. Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat. Rev. Cancer 8, 268–278 (2008).

4. Greene, K. L. et al. Prostate specific antigen best practice statement: 2009 update. J. Urol. 189, S2–S11 (2013).

5. Wang, Y. et al. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism. Asian J. Androl. 7, 375–380 (2005).

6. Prensner, J. R., Rubin, M. A., Wei, J. T. & Chinnaiyan, A. M. Beyond PSA: The next generation of prostate cancer biomarkers. Sci. Transl. Med. 4, (2012).

7. Cozar, J. M. et al. Genetic markers a landscape in prostate cancer. Mutat. Res. Mutat. Res. 775, 1–10 (2018).

8. Rittmaster, R. S., Fleshner, N. E. & Thompson, I. M. Pharmacological Approaches to Reducing the Risk of Prostate Cancer. Eur. Urol. 55, 1064–1074 (2009).

9. Mellinger, G. T., Gleason, D. & Bailar, J. The histology and prognosis of prostatic cancer. J.

Urol. 97, 331–7 (1967).

10. Epstein, J. I. An Update of the Gleason Grading System. J. Urol. 183, 433–440 (2010).

11. Calabrò, F. & Sternberg, C. N. Current Indications for Chemotherapy in Prostate Cancer Patients. Eur. Urol. 51, 17–26 (2007).

12. Egevad, L., Delahunt, B., Srigley, J. R. & Samaratunga, H. International Society of Urological Pathology (ISUP) grading of prostate cancer - An ISUP consensus on contemporary grading.

APMIS 124, 433–435 (2016).

13. Epstein, J. I., Amin, M. B., Reuter, V. E. & Humphrey, P. A. Contemporary Gleason Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 41, e1–e7 (2017).

14. Choudhury, A. D. et al. The role of genetic markers in the management of prostate cancer. Eur.

Urol. 62, 577–87 (2012).

15. Nelson, W. G., De Marzo, A. M. & Isaacs, W. B. Prostate Cancer. N. Engl. J. Med. 349, 366– 381 (2003).

16. Grignon, D. J. Unusual subtypes of prostate cancer. Mod. Pathol. 17, 316–327 (2004).

17. Hsing, A. W., Reichardt, J. K. & Stanczyk, F. Z. Hormones and prostate cancer: current perspectives and future directions. Prostate 52, 213–235 (2002).

18. Huggins, C. & Hodges, C. V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

CA Cancer J Clin 22, 232–240 (1972).

19. Angeles, A. K., Bauer, S., Ratz, L., Klauck, S. M. & Sültmann, H. Genome-Based Classification and Therapy of Prostate Cancer. Diagnostics (Basel, Switzerland) 8, (2018). 20. Makarov, D. V., Loeb, S., Getzenberg, R. H. & Partin, A. W. Biomarkers for Prostate Cancer.

Annu. Rev. Med. 60, 139–151 (2009).

21. Komiya, A. et al. Neuroendocrine differentiation in the progression of prostate cancer. Int. J.

22. Yuan, T.-C. et al. ErbB-2 via PYK2 upregulates the adhesive ability of androgen receptor- positive human prostate cancer cells. Oncogene 26, 7552–9 (2007).

23. Kokubo, H. et al. Immunohistochemical study of chromogranin A in Stage D2 prostate cancer.

Urology 66, 135–140 (2005).

24. Berruti, A. et al. Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. J. Urol. 178, 838–43; quiz 1129 (2007).

25. Boyd, L. K., Mao, X. & Lu, Y.-J. The complexity of prostate cancer: genomic alterations and heterogeneity. Nat. Rev. Urol. 9, 652–664 (2012).

26. Ross-Adams, H. et al. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. EBioMedicine 2, 1133–1144 (2015).

27. Shoag, J. & Barbieri, C. Clinical variability and molecular heterogeneity in prostate cancer.

Asian J. Androl. 18, 543 (2016).

28. Wei, L. et al. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators. Eur. Urol.

71, 183–192 (2017).

29. Tolkach, Y. & Kristiansen, G. The Heterogeneity of Prostate Cancer: A Practical Approach.

Pathobiology 85, 108–116 (2018).

30. Netto, G. J., Eich, M. L. & Varambally, S. Prostate Cancer: An Update on Molecular Pathology with Clinical Implications. Eur. Urol. Suppl. 16, 253–271 (2017).

31. Shen, M. M. & Abate-Shen, C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 24, 1967–2000 (2010).

32. Madan, R. A. & Gulley, J. L. Prostate cancer immunotherapy: the path forward. Curr. Opin.

Support. Palliat. Care 11, 225–230 (2017).

33. Sies, H. Role of metabolic H2O2 generation: redox signaling and oxidative stress. J. Biol.

Chem. 289, 8735–41 (2014).

34. Fridovich, I. & Freeman, B. Antioxidant Defenses in the Lung. Annu. Rev. Physiol. 48, 693– 702 (1986).

35. Sies, H. Strategies of antioxidant defense. Eur. J. Biochem. 215, 213–9 (1993).

36. Marinho, H. S., Real, C., Cyrne, L., Soares, H. & Antunes, F. Hydrogen peroxide sensing, signaling and regulation of transcription factors. Redox Biol. 2, 535–562 (2014).

37. Rhee, S. G. & Kil, I. S. Multiple Functions and Regulation of Mammalian Peroxiredoxins.

Annu. Rev. Biochem. 86, annurev-biochem-060815-014431 (2017).

38. Sobotta, M. C. et al. Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling. Nat.

Chem. Biol. 11, 64–70 (2015).

39. Rhee, S. G. Cell signaling. H2O2, a necessary evil for cell signaling. Science 312, 1882–3 (2006).

40. Lou, Y.-W. et al. Redox regulation of the protein tyrosine phosphatase PTP1B in cancer cells.

FEBS J. 275, 69–88 (2008).

41. Wani, R. et al. Isoform-specific regulation of Akt by PDGF-induced reactive oxygen species.

Proc. Natl. Acad. Sci. U. S. A. 108, 10550–5 (2011).

42. Song, J., Park, K. A., Lee, W. T. & Lee, J. E. Apoptosis signal regulating kinase 1 (ASK1): potential as a therapeutic target for Alzheimer’s disease. Int. J. Mol. Sci. 15, 2119–29 (2014). 43. Hamanaka, R. B. et al. Mitochondrial Reactive Oxygen Species Promote Epidermal

Differentiation and Hair Follicle Development. Sci. Signal. 6, ra8-ra8 (2013).

44. Sena, L. A. & Chandel, N. S. Physiological Roles of Mitochondrial Reactive Oxygen Species.

Mol. Cell 48, 158–167 (2012).

45. Shadel, G. S. & Horvath, T. L. Mitochondrial ROS Signaling in Organismal Homeostasis. Cell

163, 560–569 (2015).

46. Tait, S. W. G. & Green, D. R. Mitochondria and cell signalling. J. Cell Sci. 125, 807–15 (2012).

47. West, A. P., Shadel, G. S. & Ghosh, S. Mitochondria in innate immune responses. Nat. Rev.

Immunol. 11, 389–402 (2011).

48. Gabriela, V., Arciuch, A., Elguero, M. E., Poderoso, J. J. & Carreras, M. C. Mitochondrial Regulation of Cell Cycle and Proliferation. doi:10.1089/ars.2011.4085

49. Levonen, A.-L., Hill, B. G., Kansanen, E., Zhang, J. & Darley-Usmar, V. M. Redox regulation of antioxidants, autophagy, and the response to stress: Implications for electrophile therapeutics. Free Radic. Biol. Med. 71, 196–207 (2014).

50. Rajendran, P. et al. Antioxidants and human diseases. Clin. Chim. Acta 436, 332–347 (2014). 51. DeWeese, T. L., Hruszkewycz, A. M. & Marnett, L. J. Oxidative stress in chemoprevention

trials. Urology 57, 137–140 (2001).

52. Minelli, A., Bellezza, I., Conte, C. & Culig, Z. Oxidative stress-related aging: A role for prostate cancer? Biochim Biophys Acta 1795, 83–91 (2009).

53. De Marzo, A. M. et al. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 7, 256–69 (2007).

54. Khandrika, L., Kumar, B., Koul, S., Maroni, P. & Koul, H. K. Oxidative stress in prostate cancer. Cancer Lett. 282, 125–36 (2009).

55. Hawk, M. A., McCallister, C. & Schafer, Z. T. Antioxidant Activity during Tumor Progression: A Necessity for the Survival of Cancer Cells? Cancers (Basel) 8, (2016).

56. Itoh, K., Mimura, J. & Yamamoto, M. Discovery of the Negative Regulator of Nrf2, Keap1: A Historical Overview. Antioxid. Redox Signal. 13, 1665–1678 (2010).

57. Hu, R., Saw, C. L.-L., Yu, R. & Kong, A.-N. T. Regulation of NF-E2-Related Factor 2 Signaling for Cancer Chemoprevention: Antioxidant Coupled with Antiinflammatory. Antioxid.

Redox Signal. 13, 1679–1698 (2010).

58. Zhang, J. et al. C/EBPα redirects androgen receptor signaling through a unique bimodal interaction. Oncogene 29, 723–738 (2010).

59. Bostwick, D. G. et al. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 89, 123–34 (2000).

60. Ouyang, X., DeWeese, T. L., Nelson, W. G. & Abate-Shen, C. Loss-of-Function of Nkx3.1 Promotes Increased Oxidative Damage in Prostate Carcinogenesis. Cancer Res. 65, 6773–6779 (2005).

61. Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. Nat. Rev.

Cancer 11, 85–95 (2011).

62. Gorrini, C., Harris, I. S. & Mak, T. W. Modulation of oxidative stress as an anticancer strategy.

Nat Rev Drug Discov 12, 931–947 (2013).

63. Huang, P., Feng, L., Oldham, E. A., Keating, M. J. & Plunkett, W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407, 390–395 (2000).

64. Gu, L. et al. Involvement of ERK1/2 signaling pathway in DJ-1-induced neuroprotection against oxidative stress. Biochem. Biophys. Res. Commun. 383, 469–74 (2009).

65. Ma, X. et al. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer. Cancer Chemother. Pharmacol. 69, 485–494 (2012).

66. Lister, A. et al. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol. Cancer 10, 37 (2011).

7. ANEXOS